上述股份系其在首次公开发行前取得的股份，已于 2023 年 8 月 22 日起上市 流通。 减持计划的主要内容 证券代码：688271 证券简称：联影医疗 公告编号：2025-030 上海联影医疗科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，上海联影医疗科技股份有限公司（以下简称"公司" 或"联影医疗"）股东宁波梅山保税港区影聚投资管理合伙企业（有限合伙）（以 下简称"宁波影聚"）持有公司股份 11,145,243 股，占公司总股本的 1.35%；宁 波梅山保税港区影力投资管理合伙企业（有限合伙）（以下简称"宁波影力"）持 有公司股份 12,411,182 股，占公司总股本的 1.51%；宁波梅山保税港区影健投 资管理合伙企业（有限合伙）（以下简称"宁波影健"）持有公司股份 12,411,182 股，占公司总股本的 1.51%；宁波梅山保税港区影康投资管理合伙企业（有限合 伙）（以下简称"宁波影康"）持有公司股份 ...

联影医疗公告，宁波影聚、宁波影力、宁波影健、宁波影康、上海影董等员工持股平台合计持股 5458.44万股，占6.62%。因员工出售申请，计划2025年8月25日至2025年11月24日期间，通过集中竞价 减持不超过824.14万股，大宗交易减持不超过1337.66万股，合计不超过1337.66万股，占1.6231%，股份 来源为IPO前取得。 ...

融券方面，当日融券卖出0.00万股，净买入0.79万股。 来源：金融界 最近三个交易日，30日-1日，联影医疗分别获融资买入0.22亿元、0.20亿元、0.14亿元。 8月1日，沪深两融数据显示，联影医疗获融资买入额0.14亿元，居两市第950位，当日融资偿还额0.18亿 元，净卖出423.93万元。 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown positive performance, with a recent increase in its index value, indicating a growing interest and investment in the healthcare sector [1][2]. Group 1: Index Performance - The Shanghai Composite Index decreased by 0.37%, while the China Securities Index for Healthcare Equipment and Services rose by 0.47%, closing at 14,515.51 points with a trading volume of 28.859 billion [1]. - Over the past month, the China Securities Index for Healthcare Equipment and Services has increased by 6.65%, by 10.76% over the last three months, and by 6.04% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these companies [1]. - The top ten weighted companies in the index include: Mindray Medical (9.14%), United Imaging (8.05%), Aier Eye Hospital (7.32%), Aimeike (3.41%), Huatai Medical (2.89%), New Industry (2.6%), Yuyue Medical (2.57%), Lepu Medical (2.52%), Yingke Medical (2.06%), and Meinian Health (2.0%) [1]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (59.97%) and the Shanghai Stock Exchange (40.03%) [1]. Group 3: Industry Focus - The index exclusively represents the healthcare sector, with a 100% allocation to pharmaceutical and healthcare industries [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Public funds tracking the healthcare index include various funds from Southern Fund, Tianhong Fund, and others, indicating a robust interest in this sector [2].

Core Viewpoint - The Sci-Tech Innovation Board (STAR Market) has evolved into a significant platform for supporting "hard technology" enterprises in China, contributing to the development of strategic emerging industries and enhancing the country's technological self-reliance since its inception six years ago [2][3][4]. Group 1: Support for "Hard Technology" Enterprises - As of July 22, the STAR Market has supported 589 companies to go public, raising a total of 925.7 billion yuan through IPOs and 186.7 billion yuan through refinancing, exceeding 1.1 trillion yuan in total [3]. - The total market capitalization of the STAR Market has surpassed 7 trillion yuan, with ten leading companies, including Haiguang Information and SMIC, accounting for nearly 1.47 trillion yuan, representing over 20% of the total market cap [3]. - The STAR Market has facilitated the transformation of technology companies from "catching up" to "leading," significantly contributing to breakthroughs in key technologies and supporting the development of a modern industrial system [3][4]. Group 2: Reform and Innovation - The STAR Market has effectively served as a "testing ground" for reforms, implementing a registration-based IPO system and establishing a flexible and inclusive listing framework [5][6]. - It has supported 54 unprofitable companies and 8 with special share structures, with 22 of these unprofitable companies achieving profitability post-listing [6]. - The recent "1+6" policy reform aims to expand the listing standards to include fields like artificial intelligence and commercial aerospace, enhancing financing channels for cutting-edge technology firms [6][7]. Group 3: R&D Investment and Market Dynamics - In 2024, the STAR Market's R&D investment is projected to reach 168.1 billion yuan, more than three times the net profit attributable to shareholders, with a median R&D investment-to-revenue ratio of 12.6% [8]. - Approximately 90% of STAR Market companies received venture capital investment before going public, indicating a strong trend towards early-stage investment in hard technology [8]. - The STAR Market has established a comprehensive index system with 30 indices, and the total scale of products tracking these indices has reached nearly 260 billion yuan, with the STAR 50 index becoming a flagship for hard technology investments [8]. Group 4: Investor Returns and Future Outlook - 509 companies have disclosed plans for quality improvement and return actions for 2025, covering 87% of the total, with over 60% of companies proposing cash dividend plans for 2024, totaling 38.8 billion yuan [9]. - The STAR Market aims to enhance its ecosystem by optimizing listing standards, improving transparency, and providing differentiated support for technology companies at various development stages [9]. - Future initiatives include expanding financing channels and promoting cross-border technology cooperation to strengthen the global competitiveness of Chinese technology firms [9].

Core Insights - The Shanghai Composite Index decreased by 0.37%, while the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index fell by 1.74%, closing at 8507.96 points with a trading volume of 40.594 billion yuan [1] - Over the past month, the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index has increased by 17.84%, 24.27% over the last three months, and 34.48% year-to-date [1] Index Composition - The CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index is composed of 11 industry categories, reflecting the overall performance of different sectors within the index [1] - The top ten holdings in the index are: WuXi AppTec (10.42%), Hengrui Medicine (9.97%), BeiGene (9.63%), Innovent Biologics (6.64%), Mindray Medical (6.06%), WuXi Biologics (5.19%), CanSino Biologics (4.4%), China National Pharmaceutical Group (3.36%), CSPC Pharmaceutical Group (3.17%), and United Imaging Healthcare (2.85%) [1] Market Distribution - The market distribution of the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index shows that the Hong Kong Stock Exchange accounts for 37.87%, the Shanghai Stock Exchange for 33.61%, and the Shenzhen Stock Exchange for 28.52% [2] Sector Allocation - The sector allocation within the index includes: Chemical Drugs (36.20%), Pharmaceutical and Biotechnology Services (18.33%), Biopharmaceuticals (18.14%), Medical Devices (11.07%), Traditional Chinese Medicine (8.56%), and Medical Commerce and Services (7.70%) [2] Index Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] Fund Tracking - Public funds tracking the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index include the China Merchants CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare ETF [3]

Group 1 - The core viewpoint highlights the active trading and significant growth of the Science and Technology Innovation (Sci-Tech) Pharmaceutical ETF managed by Harvest, with a turnover rate of 21.72% and a transaction volume of 47.63 million yuan on July 31 [2] - Over the past week, the Sci-Tech Pharmaceutical ETF has seen an average daily transaction volume of 53.21 million yuan, ranking first among comparable funds [2] - The fund's scale increased by 16.78 million yuan in the past week, also leading among comparable funds, with a share increase of 12.50 million shares [2] Group 2 - The fund has attracted a total of 14.72 million yuan in inflows over the last five trading days [2] - As of July 31, the net value of the Sci-Tech Pharmaceutical ETF has risen by 48.77% over the past year, ranking 350 out of 2943 in the index stock fund category, placing it in the top 11.89% [2] - The fund's highest monthly return since inception was 23.29%, with the longest consecutive monthly gain being six months and a maximum increase of 41.76% [2] Group 3 - The top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [2] - The stock performance of the top ten companies shows mixed results, with some stocks experiencing slight declines while others have positive growth [4] Group 4 - The National Healthcare Security Administration has established a "new drug first launch price mechanism" to encourage drug research and innovation, marking a significant policy development [4] - The pharmaceutical and biotech sectors are expected to benefit from a high level of innovation and a potential revaluation of value stocks, with recommendations for companies in the Pharma and Biopharma/Biotech sectors [5] - The medical device industry is also anticipated to benefit from policy optimizations, with recent statements from relevant authorities supporting innovation and addressing issues of internal competition [5]

Group 1 - Overseas business development (BD) continues to exceed expectations, with CSPC Pharmaceutical Group licensing its oral GLP-1 small molecule to Madrigal for an upfront payment of $120 million, setting a record for similar transactions and highlighting the premium capability of Chinese technology platforms [1] - Breakthrough in treatment paradigm with Shuyou's C5a antibody BDB-001, which outperformed hormone therapy in treating anti-neutrophil cytoplasmic antibody vasculitis, achieving a complete response rate that is ten times higher, laying the foundation for subcutaneous formulations to enter international markets [1] - The National Healthcare Security Administration's Department of Drug Pricing and Procurement supports high-level innovative drugs to achieve returns that correspond with high investment and risk during the initial market phase, indicating a satisfactory price level, and is actively facilitating the rapid clinical introduction of new drugs through streamlined approval processes [1] Group 2 - As of August 1, 2025, the Sci-Tech Innovation Biopharmaceutical ETF (588250) has risen by 2.5%, with Zhongyin Securities noting that pharmaceutical companies are gradually overcoming the impact of centralized procurement, highlighting revaluation opportunities in the pharmaceutical sector [2] - The pharmaceutical sector is witnessing a shift in policy attitudes, with optimization of centralized procurement rules, and after years of R&D investment, new pipelines are entering a harvest phase, further evidenced by the accelerating trend of overseas BD, indicating that China's innovative drugs are becoming more competitive globally [2] - The Sci-Tech Innovation Biopharmaceutical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which selects 50 large-cap companies from various sectors, reflecting the overall performance of representative biopharmaceutical companies listed on the Sci-Tech Innovation Board [2] Group 3 - As of July 31, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) include United Imaging Healthcare, Boryung Pharmaceutical, BeiGene, Baillie Gifford, Huatai Medical, Aier Eye Hospital, Zai Lab, Junshi Biosciences, Yifan Biotech, and Teva Pharmaceutical, collectively accounting for 49.14% of the index [3]

7月31日，沪深两融数据显示，联影医疗获融资买入额0.20亿元，居两市第951位，当日融资偿还额0.31 亿元，净卖出1156.13万元。 融券方面，当日融券卖出0.03万股，净买入0.66万股。 来源：金融界 最近三个交易日，29日-31日，联影医疗分别获融资买入0.31亿元、0.22亿元、0.20亿元。 ...

Market News - US stock indices collectively declined, with the Dow Jones down 0.74%, Nasdaq down 0.03%, and S&P 500 down 0.37%. Notable tech stocks had mixed performances, with Meta rising over 11% and Microsoft nearly 4%, while Arm fell over 13% and Tesla over 3% [1] - International precious metal futures generally fell, with COMEX gold futures down 0.31% at $3342.30 per ounce and COMEX silver futures down 2.51% at $36.79 per ounce. International oil prices also decreased, with WTI crude oil down 0.91% at $69.36 per barrel and Brent crude down 0.86% at $71.85 per barrel [1] - Major European stock indices closed lower, with Germany's DAX down 0.81%, France's CAC40 down 1.14%, and the UK's FTSE 100 down 0.05% [1] Industry Insights - The State Council approved the "Artificial Intelligence +" action plan, aiming to promote the large-scale and commercial application of AI across various sectors. The release of the GLM-4.5 model indicates advancements in AI models, with expectations for significant growth in computational demand by 2025 [2] - The National Healthcare Security Administration introduced a pricing mechanism for newly listed drugs and medical technologies, including specific pricing for brain-computer interface procedures. This is expected to accelerate the clinical application of brain-computer interface technologies, with the global market projected to reach $40 billion by 2030 and $145 billion by 2040 [3] - A research team successfully converted high-quality graphite single crystal precursors into hexagonal diamond, which exhibits mechanical properties comparable to cubic diamond. This breakthrough could enhance the application of diamond in various industries, including aerospace and medical devices [4][5] Stock Movements - Wanhu Chemical announced that a shareholder plans to reduce its stake by up to 0.54% of the total share capital through centralized bidding and/or block trading [6] - Haohan Deep announced a shareholder's plan to reduce its holdings by up to 2.17% of the total share capital due to personal funding needs [6] - Tongda Co. announced a shareholder's plan to reduce its stake by up to 3% of the total share capital [6] - Heyuan Gas announced that a major shareholder intends to reduce its holdings by up to 1% of the total share capital through centralized bidding and block trading [6]